Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Mezigdomide overcomes CRBN mutations emerging post IMiD therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

EWEdmond R. WatsonCBChad C. BjorklundOPOlivia Pierce

Discussion

Loading...

Member takes

Overview

Observational study reveals mezigdomide's ability to overcome CRBN mutations in MM, indicating enhanced treatment efficacy post IMiD therapy.

Key Points

  • Investigate the impact of CRBN mutations on IMiD efficacy in multiple myeloma patients and evaluate potential mechanisms of resistance.
  • Analyzed somatic mutations in MM patients using whole genome sequencing, focusing on effects of CRBN mutations post therapy.
  • Utilized Rosetta ddG and metadynamics simulations to assess protein conformational changes and stability.
  • Conducted experimental validation of functional activities in MM cell lines harboring CRBN mutations.
  • Identified 34 unique somatic mutations in CRBN among relapsed/refractory MM patients, with no recurrent hotspots.
  • Demonstrated that mezigdomide can stabilize the A365D mutant of CRBN, enhancing receptor function for ubiquitination.
  • Functional studies showed that mezigdomide has anti-proliferative effects in cells with the A365D mutation, unlike pomalidomide.

Cite This Study

Watson et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d00ahttps://doi.org/10.1182/blood-2025-436
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pharmacodynamic activity and clinical benefits of mezigdomide in high-risk biomarker subgroups from the CC-92480-MM-001 study2025
  2. 2Targeting degradation of IKZF1 and IKZF3 through modulation of the E3 ligase substrates in the context of cellular therapies for multiple myeloma2025 · 7 citations
  3. 3Celmods potently inhibit m-MDSC induction by targeting IL-10 and MIF in multiple myeloma2025
  4. 4Immunomodulatory drugs rewire mTORC1-dependent pathways in multiple myeloma to trigger cytotoxicity and immunogenic cell death2025
  5. 5EZH2 inhibition synergizes with aiolos/ikaros degradation via coordinated chromatin remodeling and FoxO activation in multiple myeloma2025